No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
pemetrexed Sensitive: A1 - Approval
FDA - 3 days (NewA1)
|
pemetrexed Sensitive: A1 - Approval
FDA - 3 days - (New A1)
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
cisplatin + pemetrexed Sensitive: A1 - Approval
FDA - 3 days (NewA1)
|
cisplatin + pemetrexed Sensitive: A1 - Approval
FDA - 3 days - (New A1)
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
pembrolizumab Sensitive: A1 - Approval
FDA - 3 days (NewA1)
|
pembrolizumab Sensitive: A1 - Approval
FDA - 3 days - (New A1)
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
nivolumab Sensitive: A1 - Approval
N Engl J Med - 3 days (NewA1)
|
nivolumab Sensitive: A1 - Approval
N Engl J Med - 3 days - (New B)
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
atezolizumab Sensitive: A1 - Approval
Chugai Press Release - 3 days (NewA1)
|
atezolizumab Sensitive: A1 - Approval
Chugai Press Release - 3 days - (New A1)
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
alectinib Sensitive: A1 - Approval
Cancer Med - 3 days (NewA1)
|
alectinib Sensitive: A1 - Approval
Cancer Med - 3 days - (New C3)
|
EGFR exon 20 insertion
|
NSCLC
|
EGFR exon 20 insertion
|
NSCLC
|
Angiogenesis inhibitor Sensitive: C3 – Early Trials
Cancer Med - 5 days (NewC3)
|
Angiogenesis inhibitor Sensitive: C3 – Early Trials
Cancer Med - 5 days - (New C3)
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
lorlatinib Sensitive: A1 - Approval
J Clin Oncol - 6 days (NewA1)
|
lorlatinib Sensitive: A1 - Approval
J Clin Oncol - 6 days - (New B)
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
dostarlimab Sensitive: C2 – Inclusion Criteria
Clin Lung Cancer - 6 days (NewC2)
|
dostarlimab Sensitive: C2 – Inclusion Criteria
Clin Lung Cancer - 6 days - (New C3)
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials
BMC Cancer - 6 days (NewC3)
|
EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials
BMC Cancer - 6 days - (New C3)
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
sugemalimab Sensitive: A1 - Approval
CStone Pharma Press Release - 1 week (NewA1)
|
sugemalimab Sensitive: A1 - Approval
CStone Pharma Press Release - 1 week - (New B)
|
CD276 underexpression + EGFR mutation
|
LUAD
|
CD276 underexpression + EGFR mutation
|
LUAD
|
EGFR inhibitor Sensitive: C3 – Early Trials
World J Surg Oncol - 1 week (NewC3)
|
EGFR inhibitor Sensitive: C3 – Early Trials
World J Surg Oncol - 1 week - (New C3)
|
EML4-ALK fusion
|
NSCLC
|
EML4-ALK fusion
|
NSCLC
|
alectinib Sensitive: C3 – Early Trials
Int J Cancer - 1 week (NewC3)
|
alectinib Sensitive: C3 – Early Trials
Int J Cancer - 1 week - (New C3)
|
EGFR mutation + RET fusion
|
NSCLC
|
EGFR mutation + RET fusion
|
NSCLC
|
osimertinib + pralsetinib Sensitive: C3 – Early Trials
JTO Clin Res Rep - 1 week (NewC3)
|
osimertinib + pralsetinib Sensitive: C3 – Early Trials
JTO Clin Res Rep - 1 week - (New C3)
|
EML4-ALK fusion + TP53 mutation
|
NSCLC
|
EML4-ALK fusion + TP53 mutation
|
NSCLC
|
alectinib Resistant: C3 – Early Trials
Int J Cancer - 1 week (NewC3)
|
alectinib Resistant: C3 – Early Trials
Int J Cancer - 1 week - (New C3)
|
SLC12A2-ROS1 fusion
|
NSCLC
|
SLC12A2-ROS1 fusion
|
NSCLC
|
crizotinib Sensitive: C4 – Case Studies
SAGE Open Med Case Rep - 1 week (NewC4)
|
crizotinib Sensitive: C4 – Case Studies
SAGE Open Med Case Rep - 1 week - (New C4)
|
EGFR V786M
|
LUAD
|
EGFR V786M
|
LUAD
|
EGFR inhibitor Sensitive: C4 – Case Studies
Front Oncol - 1 week (NewC4)
|
EGFR inhibitor Sensitive: C4 – Case Studies
Front Oncol - 1 week - (New C4)
|
LMO7-ALK rearrangement
|
LUAD
|
LMO7-ALK rearrangement
|
LUAD
|
crizotinib Sensitive: C4 – Case Studies
Front Oncol - 1 week (NewC4)
|
crizotinib Sensitive: C4 – Case Studies
Front Oncol - 1 week - (New C4)
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
pembrolizumab Sensitive: A2 - Guideline
Int J Clin Oncol - 2 weeks (NewA2)
|
pembrolizumab Sensitive: A2 - Guideline
Int J Clin Oncol - 2 weeks - (New C3)
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
Immunotherapy Sensitive: B - Late Trials
Oncotarget - 2 weeks (NewB)
|
Immunotherapy Sensitive: B - Late Trials
Oncotarget - 2 weeks - (New C3)
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
atezolizumab + RG6058 Sensitive: B - Late Trials
Roche Press Release - 2 weeks (NewB)
|
atezolizumab + RG6058 Sensitive: B - Late Trials
Roche Press Release - 2 weeks - (New B)
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
TPX-0005 Sensitive: B - Late Trials
Turning Point Therapeutics Press Release - 2 weeks (NewB)
|
TPX-0005 Sensitive: B - Late Trials
Turning Point Therapeutics Press Release - 2 weeks - (New B)
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
durvalumab Sensitive: A1 - Approval
Precision Oncology News - 2 weeks (NewA1)
|
durvalumab Sensitive: A1 - Approval
Precision Oncology News - 2 weeks - (New A2)
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria
Lancet Oncol - 2 weeks (NewC2)
|
atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria
Lancet Oncol - 2 weeks - (New C3)
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
ALK1 inhibitor Sensitive: C3 – Early Trials
Thorac Cancer - 2 weeks (NewC3)
|
ALK1 inhibitor Sensitive: C3 – Early Trials
Thorac Cancer - 2 weeks - (New C3)
|
BRAF V600E + BRAF K601_W604del
|
NSCLC
|
BRAF V600E + BRAF K601_W604del
|
NSCLC
|
trametinib + dabrafenib Sensitive: C4 – Case Studies
Cancer Genet - 2 weeks (NewC4)
|
trametinib + dabrafenib Sensitive: C4 – Case Studies
Cancer Genet - 2 weeks - (New C4)
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
selinexor + MRTX1257 Sensitive: D – Preclinical
Cancer Res Commun - 2 weeks (NewD)
|
selinexor + MRTX1257 Sensitive: D – Preclinical
Cancer Res Commun - 2 weeks - (New D)
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
sotorasib + selinexor Sensitive: D – Preclinical
Cancer Res Commun - 2 weeks (NewD)
|
sotorasib + selinexor Sensitive: D – Preclinical
Cancer Res Commun - 2 weeks - (New D)
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
osimertinib Sensitive: A1 - Approval
ecancer - 3 weeks (NewA1)
|
osimertinib Sensitive: A1 - Approval
ecancer - 3 weeks - (New C3)
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria
Clin Drug Investig - 3 weeks (NewC2)
|
bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria
Clin Drug Investig - 3 weeks - (New C3)
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
aumolertinib Sensitive: C2 – Inclusion Criteria
J Exp Clin Cancer Res - 3 weeks (NewC2)
|
aumolertinib Sensitive: C2 – Inclusion Criteria
J Exp Clin Cancer Res - 3 weeks - (New D)
|
PD-L1 underexpression
|
NSCLC
|
PD-L1 underexpression
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
Clin Exp Immunol - 3 weeks (NewC3)
|
Immunotherapy Sensitive: C3 – Early Trials
Clin Exp Immunol - 3 weeks - (New C3)
|
MET mutation
|
NSCLC
|
MET mutation
|
NSCLC
|
Immunotherapy Resistant: C3 – Early Trials
Thorac Cancer - 3 weeks (NewC3)
|
Immunotherapy Resistant: C3 – Early Trials
Thorac Cancer - 3 weeks - (New C3)
|
SMARCA4 deletion
|
NSCLC
|
SMARCA4 deletion
|
NSCLC
|
PD-L1 inhibitor Resistant: C3 – Early Trials
Lung Cancer - 3 weeks (NewC3)
|
PD-L1 inhibitor Resistant: C3 – Early Trials
Lung Cancer - 3 weeks - (New C3)
|
EGFR T790M
|
LUAD
|
EGFR T790M
|
LUAD
|
EGFR inhibitor Sensitive: C3 – Early Trials
PLoS One - 3 weeks (NewC3)
|
EGFR inhibitor Sensitive: C3 – Early Trials
PLoS One - 3 weeks - (New C3)
|
MYC overexpression
|
NSCLC
|
MYC overexpression
|
NSCLC
|
ROS1 inhibitor Resistant: D – Preclinical
Mol Cancer Res - 3 weeks (NewD)
|
ROS1 inhibitor Resistant: D – Preclinical
Mol Cancer Res - 3 weeks - (New D)
|
ROR1 positive
|
NSCLC
|
ROR1 positive
|
NSCLC
|
LYL797 Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks (NewD)
|
LYL797 Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
|
EGFR mutation+ IDH1 R132H
|
NSCLC
|
EGFR mutation+ IDH1 R132H
|
NSCLC
|
erlotinib + AGI-5198 Sensitive: D – Preclinical
Cancer Med - 3 weeks (NewD)
|
erlotinib + AGI-5198 Sensitive: D – Preclinical
Cancer Med - 3 weeks - (New D)
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
afatinib Sensitive: A1 - Approval
|
afatinib Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
osimertinib Sensitive: A1 - Approval
|
osimertinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
ramucirumab Sensitive: A1 - Approval
|
ramucirumab Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
gefitinib Sensitive: A1 - Approval
|
gefitinib Sensitive: A1 - Approval
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
afatinib Sensitive: A1 - Approval
|
afatinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
durvalumab Sensitive: A1 - Approval
|
durvalumab Sensitive: A1 - Approval
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
ALK fusion
|
NSCLC
|
ALK fusion
|
NSCLC
|
brigatinib Sensitive: A1 - Approval
|
brigatinib Sensitive: A1 - Approval
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
sotorasib Sensitive: A1 - Approval
|
sotorasib Sensitive: A1 - Approval
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
osimertinib Sensitive: A1 - Approval
|
osimertinib Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
brigatinib Sensitive: A1 - Approval
|
brigatinib Sensitive: A1 - Approval
|
ROS1 fusion
|
NSCLC
|
ROS1 fusion
|
NSCLC
|
entrectinib Sensitive: A1 - Approval
|
entrectinib Sensitive: A1 - Approval
|
MET exon 14 mutation
|
NSCLC
|
MET exon 14 mutation
|
NSCLC
|
tepotinib Sensitive: A1 - Approval
|
tepotinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
dacomitinib Sensitive: A1 - Approval
|
dacomitinib Sensitive: A1 - Approval
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
lazertinib Sensitive: A1 - Approval
|
lazertinib Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
dacomitinib Sensitive: A1 - Approval
|
dacomitinib Sensitive: A1 - Approval
|
MET exon 14 mutation
|
NSCLC
|
MET exon 14 mutation
|
NSCLC
|
capmatinib Sensitive: A1 - Approval
|
capmatinib Sensitive: A1 - Approval
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
cemiplimab Sensitive: A1 - Approval
|
cemiplimab Sensitive: A1 - Approval
|
RET fusion
|
NSCLC
|
RET fusion
|
NSCLC
|
pralsetinib Sensitive: A1 - Approval
|
pralsetinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
cisplatin + pemetrexed Sensitive: A1 - Approval
|
cisplatin + pemetrexed Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
gefitinib Sensitive: A1 - Approval
|
gefitinib Sensitive: A1 - Approval
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
gefitinib Sensitive: A1 - Approval
|
gefitinib Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
cisplatin Sensitive: A1 - Approval
|
cisplatin Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
crizotinib Sensitive: A1 - Approval
|
crizotinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
crizotinib Sensitive: A1 - Approval
|
crizotinib Sensitive: A1 - Approval
|
RET fusion
|
NSCLC
|
RET fusion
|
NSCLC
|
selpercatinib Sensitive: A1 - Approval
|
selpercatinib Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
afatinib Sensitive: A1 - Approval
|
afatinib Sensitive: A1 - Approval
|
EGFR exon 20 insertion
|
NSCLC
|
EGFR exon 20 insertion
|
NSCLC
|
mobocertinib Sensitive: A1 - Approval
|
mobocertinib Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
erlotinib Sensitive: A1 - Approval
|
erlotinib Sensitive: A1 - Approval
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
tislelizumab Sensitive: A1 - Approval
|
tislelizumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
DP Sensitive: A1 - Approval
|
DP Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
ensartinib Sensitive: A1 - Approval
|
ensartinib Sensitive: A1 - Approval
|
MET exon 14 mutation
|
NSCLC
|
MET exon 14 mutation
|
NSCLC
|
savolitinib Sensitive: A1 - Approval
|
savolitinib Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
dacomitinib Sensitive: A1 - Approval
|
dacomitinib Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
erlotinib Sensitive: A1 - Approval
|
erlotinib Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
pemetrexed Sensitive: A1 - Approval
|
pemetrexed Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval
|
carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval
|
No biomarker
|
LUAD
|
No biomarker
|
LUAD
|
nintedanib Sensitive: A1 - Approval
|
nintedanib Sensitive: A1 - Approval
|
EGFR expression
|
Lung Non-Small Cell Squamous Cancer
|
EGFR expression
|
Lung Non-Small Cell Squamous Cancer
|
necitumumab Sensitive: A1 - Approval
|
necitumumab Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
BRAF V600E
|
NSCLC
|
BRAF V600E
|
NSCLC
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
EGFR exon 20 insertion
|
NSCLC
|
EGFR exon 20 insertion
|
NSCLC
|
amivantamab-vmjw Sensitive: A1 - Approval
|
amivantamab-vmjw Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
docetaxel Sensitive: A1 - Approval
|
docetaxel Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
erlotinib Sensitive: A1 - Approval
|
erlotinib Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
ceritinib Sensitive: A1 - Approval
|
ceritinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
afatinib Sensitive: A1 - Approval
|
afatinib Sensitive: A1 - Approval
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
aumolertinib Sensitive: A1 - Approval
|
aumolertinib Sensitive: A1 - Approval
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + erlotinib Sensitive: A1 - Approval
|
bevacizumab + erlotinib Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
sintilimab Sensitive: A1 - Approval
|
sintilimab Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
erlotinib + ramucirumab Sensitive: A1 - Approval
|
erlotinib + ramucirumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
ALK mutation
|
NSCLC
|
ALK mutation
|
NSCLC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
erlotinib Sensitive: A1 - Approval
|
erlotinib Sensitive: A1 - Approval
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
erlotinib + ramucirumab Sensitive: A1 - Approval
|
erlotinib + ramucirumab Sensitive: A1 - Approval
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
entrectinib Sensitive: A1 - Approval
|
entrectinib Sensitive: A1 - Approval
|
BRAF V600
|
NSCLC
|
BRAF V600
|
NSCLC
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
afatinib Sensitive: A1 - Approval
|
afatinib Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
tislelizumab Sensitive: A1 - Approval
|
tislelizumab Sensitive: A1 - Approval
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
ALK mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
cemiplimab Sensitive: A1 - Approval
|
cemiplimab Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
sintilimab Sensitive: A1 - Approval
|
sintilimab Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
EGFR mutation + ALK negative + TMB-H
|
NSCLC
|
EGFR mutation + ALK negative + TMB-H
|
NSCLC
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
ROS1 fusion
|
NSCLC
|
ROS1 fusion
|
NSCLC
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
BRAF V600E
|
NSCLC
|
BRAF V600E
|
NSCLC
|
dabrafenib Sensitive: A2 - Guideline
|
dabrafenib Sensitive: A2 - Guideline
|
ROS1 rearrangement
|
NSCLC
|
ROS1 rearrangement
|
NSCLC
|
ceritinib Sensitive: A2 - Guideline
|
ceritinib Sensitive: A2 - Guideline
|
ROS1 rearrangement
|
NSCLC
|
ROS1 rearrangement
|
NSCLC
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
ALK rearrangement
|
NSCLC
|
ALK rearrangement
|
NSCLC
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
ALK rearrangement
|
NSCLC
|
ALK rearrangement
|
NSCLC
|
alectinib Sensitive: A2 - Guideline
|
alectinib Sensitive: A2 - Guideline
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
lorlatinib Sensitive: A2 - Guideline
|
lorlatinib Sensitive: A2 - Guideline
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
osimertinib Sensitive: A2 - Guideline
|
osimertinib Sensitive: A2 - Guideline
|
ALK rearrangement
|
NSCLC
|
ALK rearrangement
|
NSCLC
|
ALK inhibitor Sensitive: A2 - Guideline
|
ALK inhibitor Sensitive: A2 - Guideline
|